In clinical samples representing melanoma progression [primary tumors (n=102), subcutaneous tumors (regional cutaneous and in-transit metastasis, n=74), regional lymph node (n=221) and distant metastasis (n=68)], RMEL3 expression was increased in subcutaneous tumors compared to primary tumors (Figure 1C). This evidence concerns the gene RMEL3 and melanoma.